Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.86
PDLI's Cash to Debt is ranked lower than
82% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. PDLI: 0.86 )
Ranked among companies with meaningful Cash to Debt only.
PDLI' s Cash to Debt Range Over the Past 10 Years
Min: 0.25  Med: 0.81 Max: No Debt
Current: 0.86
Equity to Asset 0.69
PDLI's Equity to Asset is ranked higher than
50% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. PDLI: 0.69 )
Ranked among companies with meaningful Equity to Asset only.
PDLI' s Equity to Asset Range Over the Past 10 Years
Min: -1.85  Med: 0.53 Max: 0.96
Current: 0.69
-1.85
0.96
Interest Coverage 20.34
PDLI's Interest Coverage is ranked lower than
75% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PDLI: 20.34 )
Ranked among companies with meaningful Interest Coverage only.
PDLI' s Interest Coverage Range Over the Past 10 Years
Min: 4.85  Med: 14.64 Max: 20.34
Current: 20.34
4.85
20.34
F-Score: 5
Z-Score: 4.96
M-Score: 173.41
WACC vs ROIC
6.08%
53.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 93.21
PDLI's Operating margin (%) is ranked higher than
98% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. PDLI: 93.21 )
Ranked among companies with meaningful Operating margin (%) only.
PDLI' s Operating margin (%) Range Over the Past 10 Years
Min: -32.28  Med: 92.61 Max: 94.93
Current: 93.21
-32.28
94.93
Net-margin (%) 56.36
PDLI's Net-margin (%) is ranked higher than
96% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. PDLI: 56.36 )
Ranked among companies with meaningful Net-margin (%) only.
PDLI' s Net-margin (%) Range Over the Past 10 Years
Min: -31.35  Med: 55.26 Max: 59.72
Current: 56.36
-31.35
59.72
ROE (%) 60.92
PDLI's ROE (%) is ranked higher than
98% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. PDLI: 60.92 )
Ranked among companies with meaningful ROE (%) only.
PDLI' s ROE (%) Range Over the Past 10 Years
Min: -26.17  Med: 72.89 Max: 1166.18
Current: 60.92
-26.17
1166.18
ROA (%) 32.57
PDLI's ROA (%) is ranked higher than
98% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. PDLI: 32.57 )
Ranked among companies with meaningful ROA (%) only.
PDLI' s ROA (%) Range Over the Past 10 Years
Min: -11.28  Med: 38.22 Max: 77.05
Current: 32.57
-11.28
77.05
ROC (Joel Greenblatt) (%) 2040.85
PDLI's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. PDLI: 2040.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PDLI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -39.68  Med: 2574.80 Max: 673588.24
Current: 2040.85
-39.68
673588.24
Revenue Growth (3Y)(%) 12.20
PDLI's Revenue Growth (3Y)(%) is ranked higher than
63% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. PDLI: 12.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PDLI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -88.7  Med: 13.50 Max: 1003.4
Current: 12.2
-88.7
1003.4
EBITDA Growth (3Y)(%) 11.80
PDLI's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. PDLI: 11.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PDLI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -38.8  Med: 15.75 Max: 857.4
Current: 11.8
-38.8
857.4
EPS Growth (3Y)(%) 12.10
PDLI's EPS Growth (3Y)(%) is ranked higher than
70% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. PDLI: 12.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PDLI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -89.4  Med: 11.35 Max: 798.3
Current: 12.1
-89.4
798.3
» PDLI's 10-Y Financials

Financials (Next Earnings Date: 2016-05-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

PDLI Guru Trades in Q1 2015

Barrow, Hanley, Mewhinney & Strauss 262,299 sh (New)
Joel Greenblatt 3,365,474 sh (+1739.03%)
Paul Tudor Jones 118,200 sh (+73.06%)
Jim Simons 11,971,554 sh (+1.70%)
First Eagle Investment 2,800 sh (unchged)
» More
Q2 2015

PDLI Guru Trades in Q2 2015

Joel Greenblatt 7,233,838 sh (+114.94%)
Barrow, Hanley, Mewhinney & Strauss 276,491 sh (+5.41%)
First Eagle Investment 2,800 sh (unchged)
Jim Simons 11,532,754 sh (-3.67%)
Paul Tudor Jones 87,000 sh (-26.40%)
» More
Q3 2015

PDLI Guru Trades in Q3 2015

Jeremy Grantham 199,000 sh (New)
Barrow, Hanley, Mewhinney & Strauss 276,491 sh (unchged)
First Eagle Investment 2,800 sh (unchged)
Jim Simons 8,996,154 sh (-21.99%)
Joel Greenblatt 5,046,353 sh (-30.24%)
Paul Tudor Jones 44,900 sh (-48.39%)
» More
Q4 2015

PDLI Guru Trades in Q4 2015

Paul Tudor Jones 125,900 sh (+180.40%)
Jim Simons 10,345,559 sh (+15.00%)
Barrow, Hanley, Mewhinney & Strauss 281,746 sh (+1.90%)
First Eagle Investment 2,800 sh (unchged)
Jeremy Grantham 196,700 sh (-1.16%)
Joel Greenblatt 4,748,690 sh (-5.90%)
» More
» Details

Insider Trades

Latest Guru Trades with PDLI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about PDL BioPharma Inc

Undervalued Companies With Growing EPS Atwood Oceanics and NeuStar have a wide margin of safety
Companies with growing EPS are often a good investment as they can return a very good profit to investors. Here is a selection of the most undervalued companies according to the DCF calculator that have a five-year growing EPS. Read more...
Weekly 3-Year Low Highlights: APOL, PDLI, TC, ALLT, ELRC
According to GuruFocus list of 3-year lows, Apollo Education Group Inc, PDL BioPharma Inc, Thompson Creek Metals Co Inc, Allot Communications Ltd, and Electro Rent Corp have all reached their 3-year lows. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 1.83
PDLI's P/E(ttm) is ranked higher than
97% of the 239 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. PDLI: 1.83 )
Ranked among companies with meaningful P/E(ttm) only.
PDLI' s P/E(ttm) Range Over the Past 10 Years
Min: 1.46  Med: 5.36 Max: 24.66
Current: 1.83
1.46
24.66
Forward P/E 52.91
PDLI's Forward P/E is ranked lower than
86% of the 85 Companies
in the Global Biotechnology industry.

( Industry Median: 17.79 vs. PDLI: 52.91 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 1.83
PDLI's PE(NRI) is ranked higher than
97% of the 242 Companies
in the Global Biotechnology industry.

( Industry Median: 30.06 vs. PDLI: 1.83 )
Ranked among companies with meaningful PE(NRI) only.
PDLI' s PE(NRI) Range Over the Past 10 Years
Min: 1.46  Med: 5.30 Max: 61.63
Current: 1.83
1.46
61.63
Price/Owner Earnings (ttm) 1.67
PDLI's Price/Owner Earnings (ttm) is ranked higher than
95% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 36.86 vs. PDLI: 1.67 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
PDLI' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 1.32  Med: 6.18 Max: 70.2
Current: 1.67
1.32
70.2
P/B 0.86
PDLI's P/B is ranked higher than
93% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. PDLI: 0.86 )
Ranked among companies with meaningful P/B only.
PDLI' s P/B Range Over the Past 10 Years
Min: 0.69  Med: 3.42 Max: 38.99
Current: 0.86
0.69
38.99
P/S 1.04
PDLI's P/S is ranked higher than
94% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. PDLI: 1.04 )
Ranked among companies with meaningful P/S only.
PDLI' s P/S Range Over the Past 10 Years
Min: 0.82  Med: 3.16 Max: 14.21
Current: 1.04
0.82
14.21
POCF 1.99
PDLI's POCF is ranked higher than
99% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. PDLI: 1.99 )
Ranked among companies with meaningful POCF only.
PDLI' s POCF Range Over the Past 10 Years
Min: 1.61  Med: 6.32 Max: 74.47
Current: 1.99
1.61
74.47
EV-to-EBIT 1.16
PDLI's EV-to-EBIT is ranked higher than
90% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. PDLI: 1.16 )
Ranked among companies with meaningful EV-to-EBIT only.
PDLI' s EV-to-EBIT Range Over the Past 10 Years
Min: -64.4  Med: 3.90 Max: 147.7
Current: 1.16
-64.4
147.7
EV-to-EBITDA 1.14
PDLI's EV-to-EBITDA is ranked higher than
90% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. PDLI: 1.14 )
Ranked among companies with meaningful EV-to-EBITDA only.
PDLI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -29.8  Med: 3.90 Max: 158.9
Current: 1.14
-29.8
158.9
PEG 0.08
PDLI's PEG is ranked higher than
99% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 2.25 vs. PDLI: 0.08 )
Ranked among companies with meaningful PEG only.
PDLI' s PEG Range Over the Past 10 Years
Min: 0.06  Med: 0.25 Max: 4.81
Current: 0.08
0.06
4.81
Shiller P/E 4.09
PDLI's Shiller P/E is ranked higher than
92% of the 51 Companies
in the Global Biotechnology industry.

( Industry Median: 54.60 vs. PDLI: 4.09 )
Ranked among companies with meaningful Shiller P/E only.
PDLI' s Shiller P/E Range Over the Past 10 Years
Min: 3.28  Med: 16.88 Max: 209.25
Current: 4.09
3.28
209.25
Current Ratio 7.69
PDLI's Current Ratio is ranked higher than
67% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. PDLI: 7.69 )
Ranked among companies with meaningful Current Ratio only.
PDLI' s Current Ratio Range Over the Past 10 Years
Min: 0.26  Med: 8.45 Max: 57.61
Current: 7.69
0.26
57.61
Quick Ratio 7.69
PDLI's Quick Ratio is ranked higher than
68% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. PDLI: 7.69 )
Ranked among companies with meaningful Quick Ratio only.
PDLI' s Quick Ratio Range Over the Past 10 Years
Min: 0.26  Med: 8.45 Max: 57.61
Current: 7.69
0.26
57.61
Days Sales Outstanding 36.10
PDLI's Days Sales Outstanding is ranked higher than
73% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. PDLI: 36.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
PDLI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.19  Med: 0.90 Max: 36.1
Current: 36.1
0.19
36.1

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 13.70
PDLI's Dividend Yield is ranked higher than
99% of the 206 Companies
in the Global Biotechnology industry.

( Industry Median: 1.33 vs. PDLI: 13.70 )
Ranked among companies with meaningful Dividend Yield only.
PDLI' s Dividend Yield Range Over the Past 10 Years
Min: 2.26  Med: 7.93 Max: 20.55
Current: 13.7
2.26
20.55
Dividend Payout 0.29
PDLI's Dividend Payout is ranked higher than
55% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 0.33 vs. PDLI: 0.29 )
Ranked among companies with meaningful Dividend Payout only.
PDLI' s Dividend Payout Range Over the Past 10 Years
Min: 0.3  Med: 0.36 Max: 0.53
Current: 0.29
0.3
0.53
Forward Dividend Yield 5.31
PDLI's Forward Dividend Yield is ranked higher than
94% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 1.33 vs. PDLI: 5.31 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 13.70
PDLI's Yield on cost (5-Year) is ranked higher than
98% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 1.55 vs. PDLI: 13.70 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
PDLI' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.26  Med: 7.93 Max: 20.55
Current: 13.7
2.26
20.55
3-Year Average Share Buyback Ratio -3.80
PDLI's 3-Year Average Share Buyback Ratio is ranked higher than
70% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.70 vs. PDLI: -3.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PDLI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -958.2  Med: -4.60 Max: 89.4
Current: -3.8
-958.2
89.4

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 2.02
PDLI's Price/Tangible Book is ranked higher than
76% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. PDLI: 2.02 )
Ranked among companies with meaningful Price/Tangible Book only.
PDLI' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.99  Med: 3.70 Max: 31.88
Current: 2.02
0.99
31.88
Price/Projected FCF 0.58
PDLI's Price/Projected FCF is ranked higher than
97% of the 176 Companies
in the Global Biotechnology industry.

( Industry Median: 3.66 vs. PDLI: 0.58 )
Ranked among companies with meaningful Price/Projected FCF only.
PDLI' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.57  Med: 3.18 Max: 47.69
Current: 0.58
0.57
47.69
Price/Median PS Value 0.32
PDLI's Price/Median PS Value is ranked higher than
89% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. PDLI: 0.32 )
Ranked among companies with meaningful Price/Median PS Value only.
PDLI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.05  Med: 2.55 Max: 20.46
Current: 0.32
0.05
20.46
Price/Peter Lynch Fair Value 0.08
PDLI's Price/Peter Lynch Fair Value is ranked higher than
98% of the 57 Companies
in the Global Biotechnology industry.

( Industry Median: 1.86 vs. PDLI: 0.08 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
PDLI' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.08  Med: 0.28 Max: 0.62
Current: 0.08
0.08
0.62
Price/Graham Number 0.41
PDLI's Price/Graham Number is ranked higher than
90% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. PDLI: 0.41 )
Ranked among companies with meaningful Price/Graham Number only.
PDLI' s Price/Graham Number Range Over the Past 10 Years
Min: 0.39  Med: 2.00 Max: 29.42
Current: 0.41
0.39
29.42
Earnings Yield (Greenblatt) (%) 87.32
PDLI's Earnings Yield (Greenblatt) (%) is ranked higher than
97% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. PDLI: 87.32 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PDLI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.7  Med: 24.40 Max: 108.2
Current: 87.32
0.7
108.2
Forward Rate of Return (Yacktman) (%) 30.35
PDLI's Forward Rate of Return (Yacktman) (%) is ranked higher than
76% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 13.93 vs. PDLI: 30.35 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
PDLI' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -8.7  Med: 0.90 Max: 44.2
Current: 30.35
-8.7
44.2

More Statistics

Revenue(Mil) $590
EPS $ 2.01
Beta0.66
Short Percentage of Float9.15%
52-Week Range $2.58 - 6.85
Shares Outstanding(Mil)164.29

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 213 69 64
EPS($) 0.62 0.07 0.15
EPS without NRI($) 0.62 0.07 0.15

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:MACK, SZSE:002604, XMCE:ROVI, NAS:CEMP, XBRU:ABLX, ROCO:4105 » details
Traded in other countries:PDL.Germany,
PDL BioPharma Inc was organized as a Delaware corporation in 1986 under the name Protein Design Labs, Inc. In 2006, the Company changed its name to PDL BioPharma, Inc. The Company is engaged in the discovery of a new generation of targeted treatments for cancer and immunologic diseases. The Company focuses on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. It manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. Its Queen et al. patents, covers among other things, humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies and methods of producing humanized antibodies. It's U.S. Patent; covers methods and materials used in the manufacture of humanized antibodies. The Company entered into licensing agreements under Queen et al. patents with entities that are independently developing or have developed humanized antibodies. The Company entered into patents license agreement with Genentech, Biogen Idec and Chugai; and it entered into a royalty purchase and sale agreement with Depomed, Inc. As on year ended December 31, 2013, the Company received Queen et al. patent royalties on sales of the eight humanized antibody products, all of which are currently approved for use by the FDA and other regulatory agencies outside the United States; including, Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, Tysabri and Actemra. The Company has also entered into licensing agreements under which it has licensed certain rights for development stage products that have not yet reached commercialization including products that are currently in Phase 3 clinical trials. The Company faces competition from other royalty buyers and enterprises. The Company's licensees, borrowers and royalty-agreement counterparties are subject to stringent regulation with respect to product safety and efficacy by various international, federal, state and local authorities.
» More Articles for NAS:PDLI

Headlines

Articles On GuruFocus.com
Undervalued Companies With Growing EPS Apr 04 2016 
Cash is Flowing Nicely for These Five Stocks Aug 19 2015 
Context Capital Management's Top Buys in Q2 2015 Jul 15 2015 
Weekly 3-Year Low Highlights: APOL, PDLI, TC, ALLT, ELRC May 17 2015 
Hot Picks with High Yields Jul 23 2013 
My 3 Favorite Healthcare Dividend Stocks with Highest Float Short Ratio Jun 03 2013 
My 4 Favorites From The 20 Cheapest Healthcare Dividend Stock List May 02 2013 
68 Top-Yielding Stocks with Ex-Dividend Date in March 2013 Feb 27 2013 
20 Best Yielding Healthcare Growth Stocks and Which to Buy Feb 02 2013 
Seth Klarman’s Investment Framework Sep 15 2012 

More From Other Websites
PDL BioPharma to Announce First Quarter 2016 Financial Results on May 4, 2016 Apr 28 2016
PDL BioPharma to Announce First Quarter 2016 Financial Results on May 4, 2016 Apr 28 2016
Undervalued Companies With Growing EPS Apr 04 2016
PDL BioPharma to Hold Annual Meeting of Stockholders on June 2, 2016 Mar 31 2016
PDL BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 31 2016
PDL BioPharma to Hold Annual Meeting of Stockholders on June 2, 2016 Mar 31 2016
PDL BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : PDLI-US : March 16,... Mar 16 2016
PDL BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 14 2016
PDL BioPharma Completes Quarterly Dividend Payment Mar 14 2016
PDL BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 07 2016
PDL BioPharma to Present at the Cowen and Company 36th Annual Health Care Conference Mar 02 2016
PDL BIOPHARMA, INC. Financials Feb 26 2016
PDL BioPharma, Inc. Earnings Analysis: 2015 By the Numbers Feb 24 2016
PDL BioPharma Beats on Q4 Earnings, Revenues Up Y/Y Feb 24 2016
PDL BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 24 2016
PDL BIOPHARMA, INC. Files SEC form 10-K, Annual Report Feb 23 2016
Edited Transcript of PDLI earnings conference call or presentation 22-Feb-16 9:30pm GMT Feb 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK